Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues ...

In this new analysis, the Company reported changes in plasma biomarkers that may reflect Alzheimer's disease pathology. The results demonstrated that individuals who entered the study with plasma ...

Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...

Doctors call that a “primary” cause of nephrotic syndrome. Or you might have an issue with another part of your body that also affects your kidneys. That’s called a “secondary” cause of ...

and insoluble forms of amyloid-beta (Aβ). Lecanemab’s Positive Opinion from the CHMP in the European Union was primarily based on Phase 3 data from Eisai’s global Clarity AD clinical trial, in which ...

With a degree in secondary education, you can play a primary role in developing these students into adolescents who are well-equipped to embark on new journeys. These degrees explore teaching ...

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment ...